A recent study by researchers at Johns Hopkins University and the University of California San Diego indicates substantial public support for medical cannabis rescheduling in the United States. The findings, published in the journal Addiction, emerge as the federal government, under the Trump administration, reclassified state-licensed medical marijuana from a Schedule I drug to a less restrictive Schedule III. This move, while significant, appears to be viewed by a majority of the public as an initial step towards broader reform, according to analysis of over 40,000 public comments.
Public Sentiment on Cannabis Rescheduling
The study leveraged artificial intelligence to analyze 42,913 public comments submitted to the Drug Enforcement Administration’s (DEA) e-rulemaking portal. This unprecedented volume of public input followed a 2024 DEA proposal concerning marijuana rescheduling, with the comment window spanning 63 days. The research team, as detailed by Medical Xpress, obtained every comment and employed an AI-driven analysis, validated against human review, to characterize public opinion.
Analysis of Public Comments
The analysis revealed a strong consensus for change, with 92.4% of commenters advocating for cannabis to be moved off Schedule I. Specifically, the sentiment broke down as follows:
- 63.5% supported even more reform than proposed, often calling for full descheduling.
- 28.9% supported the proposed Schedule III reclassification.
- 6.7% opposed any change to cannabis’s Schedule I status.
Vijay M. Tiyyala, a Johns Hopkins research assistant and first author of the study, noted that “Americans showed up with their personal stories about therapy that helped them, businesses they built, consequences of cannabis use, and more,” as reported by the Johns Hopkins University Hub.
Motivations for Reform
Supporters of the Schedule III reclassification, including patients, healthcare providers, and business owners, frequently cited personal experiences. Their primary motivations included:
- Therapeutic benefits (56.7% of supporters).
- Economic impacts on the cannabis industry and state revenues (27.8%).
- The need for clearer federal regulation to ensure public safety (24.4%).
For those advocating for full descheduling, which would remove cannabis from federal control entirely, motivations also centered on therapeutic benefits (37.8%) and economic impacts (28.6%). Additionally, this group prominently cited criminal justice reform (26.5%) and social justice concerns regarding disproportionate incarceration in marginalized communities, which appeared in approximately one in five of their comments.
Implications for Research and Policy
The reclassification of cannabis to Schedule III is anticipated to have significant implications for scientific inquiry. Ryan Vandrey, a cannabis researcher at Johns Hopkins and co-author, stated that this change “will expand the type of research that can be conducted as well as the pool of scientists who can engage in research on the health effects of cannabis use.” This expansion is critical for developing an evidence base that matches the public’s enthusiasm for cannabis as medicine, as previously highlighted in Hemp Gazette coverage regarding the volume of public submissions to the DEA.
Addressing Public Health Concerns
The minority group opposing any change to cannabis’s Schedule I status primarily raised public health concerns. Their arguments focused on:
- Public health risks (100% of opponents).
- Addictiveness (71.4%).
- Potential harms to children and adolescents (57.1%), with parental concerns about youth access being a significant factor.
These concerns underscore the ongoing debate surrounding the public health implications of cannabis policy reform.
John W. Ayers, senior author and vice chief of innovation at UC San Diego School of Medicine, concluded that while “Rescheduling is a meaningful first step, the public record shows Americans want federal policy to go even further.” The study also demonstrated the utility of AI-driven analyses in processing large volumes of public input, potentially revolutionizing how citizens engage with democratic processes, according to Mark Dredze, a computer scientist at Johns Hopkins and co-author.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
